Get started
Author

Claire S. Padgett

Observed names: C. S. Padgett, C.S. Padgett, Claire Padgett
OpenAlex ID: A5077486206
Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis
2019 · Paolo Raggi, Antonio Bellasi, et al. · Circulation · 161
PDF
Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer
2011 · Denis Drygin, Caroline B. Ho, et al. · Biochemical and Biophysical Research Communications · 72
Steady‐State Pharmacokinetics of Zonisamide, an Antiepileptic Agent for Treatment of Refractory Complex Partial Seizures
1998 · Gregory M. Kochak, John G. Page, et al. · The Journal of Clinical Pharmacology · 58
Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2.
2011 · R. F. Marschke, M. J. Borad, et al. · Journal of Clinical Oncology · 49
Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease
2021 · James F. Casella, Bruce A. Barton, et al. · JAMA · 39
PDF
The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis
2021 · Smeeta Sinha, Lisa J Gould, et al. · Clinical Kidney Journal · 38
PDF
414 Clinical pharmacokinetics and pharmacodynamics of CX-4945, a novel inhibitor of protein kinase CK2: Interim report from the phase 1 clinical trial
2010 · C.S. Padgett, J.K.C. Lim, et al. · European Journal of Cancer Supplements · 16
Pharmacokinetic findings from the phase I study of Quarfloxin (CX-3543): a protein-rDNA quadruplex inhibitor, in patients with advanced solid tumors.
2007 · Kyriakos P. Papadopoulos, Alain C. Mita, et al. · Molecular Cancer Therapeutics · 11
Phase I clinical trial of quarfloxin administered weekly×3 of a four week cycle
2008 · T. R. Fitch, D. W. Northfelt, et al. · Journal of Clinical Oncology · 3
Pharmacokinetics, Safety, and Tolerability of Anti‐miR‐17 Oligonucleotide RGLS4326 in Healthy Adult Subjects
2026 · Tate Owen, Izaiah Cole, et al. · The Journal of Clinical Pharmacology · 2
Farabursen Increases Urinary Polycystin-1 and Polycystin-2 and Reduces Height-Adjusted Total Kidney Volume Growth in Patients with ADPKD
2025 · Alan S.L. Yu, Rekha Garg, et al. · Journal of the American Society of Nephrology · 2
RGLS8429 Increases Urinary PC1 and PC2 and May Reduce Height-Adjusted Total Kidney Volume (htTKV) in Patients with ADPKD
2024 · Alan S.L. Yu, Rekha Garg, et al. · Journal of the American Society of Nephrology · 2
Abstract C39: Phase I clinical trial of CX-4945: A first-in-class orally administered small molecule inhibitor of protein kinase CK2
2009 · Robert F. Marschke, Eleni Andreopoulou, et al. · Molecular Cancer Therapeutics · 2
Abstract 2763: Utility of clinical biomarkers for detecting protein kinase CK2 inhibition: A report from the phase I trial of CX-4945
2010 · John K.C. Lim, Claire S. Padgett, et al. · Cancer Research · 1
Wcn26-7987 Farabursen Increases Urinary Polycystin 1 and 2 and Reduces Height-adjusted Total Kidney Volume Growth in Patients With Autosomal Dominant Polycystic Kidney Disease
2026 · Alan S. Yu, Rekha Garg, et al. · Kidney International Reports
Abstract 9793: Walking Performance, Quality of Life, and Hemodynamic Characteristics in Patients with Peripheral Artery Disease and End-Stage Kidney Disease (PAD-ESKD)
2021 · Naomi Hamburg, Alik Farber, et al. · Circulation
SNF472 Consistently Slows Progression of Coronary Artery Calcification Across Subgroups of Patients on Hemodialysis
2020 · Glenn M. Chertow, Paolo Raggi, et al. · Journal of the American Society of Nephrology
So086snf472 Consistently Slows Progression of Coronary Calcification in Patients on Hemodialysis: Subgroup Analysis of the Calipso Study
2020 · Paolo Raggi, Antonio Bellasi, et al. · Nephrology Dialysis Transplantation
PDF
Works count: 18
Citation count: 456
H-index: 8
I10-index: 8
Year
Topic
Type